| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Vyome Holdings, Inc | Chief Financial Officer | Common Stock | 762 | $342 | $0.45 | Aug 15, 2025 | Direct |
| AngioGenex, Inc. | Director, INDEPENDENT DIRECTOR | Stock Option | 850K | Sep 2, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| HIND | Vyome Holdings, Inc | Aug 15, 2025 | 1 | $0 | 4 | Sep 11, 2025 | Chief Financial Officer |
| HIND | Vyome Holdings, Inc | Aug 15, 2025 | 0 | $0 | 3 | Sep 11, 2025 | Chief Financial Officer |
| NVTA | Invitae Corp | Aug 14, 2023 | 0 | $0 | 3 | Aug 17, 2023 | Interim Chief Financial Officer Exhibit List: Exhibit 24 - Power of Attorney |
| ENVB | Enveric Biosciences, Inc. | Sep 9, 2022 | 0 | $0 | 3 | Sep 23, 2022 | Chief Financial Officer |
| AIM | AIM ImmunoTech Inc. | Apr 4, 2022 | 0 | $0 | 3 | Apr 4, 2022 | Chief Financial Officer |
| AGGX | AngioGenex, Inc. | Dec 31, 2021 | 1 | $32.5K | 5 | Feb 16, 2022 | Director, INDEPENDENT DIRECTOR |